Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents

被引：8
|
作者：
Rizzo, Renata [1 ]
Martino, Davide [2 ,3 ]
机构：
[1] Univ Catania, Neuropsichiatria Infantile, Dipartimento Sci Med & Pediat, I-95123 Catania, Italy
[2] Kings Coll Hosp NHS Fdn Trust, Dept Neurol, London, England
[3] Queen Elizabeth Hosp, Lewisham & Greenwich NHS Trust, London, England
来源：
EXPERT REVIEW OF NEUROTHERAPEUTICS | 2015年 / 15卷 / 04期
关键词：
alpha(2)-adrenoreceptor agonist; attention deficit hyperactivity disorder; guanfacine extended-release; guanfacine immediate-release; treatment; EXTENDED-RELEASE; DEFICIT/HYPERACTIVITY DISORDER; DOUBLE-BLIND; OPEN-LABEL; LONG-TERM; PHASE-I; ADHD; PHARMACOKINETICS; PSYCHOSTIMULANTS; NEUROBIOLOGY;
D O I：
10.1586/14737175.2015.1028370
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Guanfacine is an (2A)-adrenoreceptor agonist currently indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This article reviews the chemistry, pharmacodynamics and pharmacokinetics of guanfacine, as well as the clinical trial literature on guanfacine for the treatment of ADHD in children and adolescents, mainly focusing on the use of guanfacine extended-release (GXR). Six already published prospective randomized controlled trials (RCTs) and one unpublished RCT study were identified for GXR in the treatment of ADHD. All RCTs trials showed superiority over placebo on the primary outcome measure. Guanfacine, especially XR, seems to be an effective and safe treatment option for ADHD in children and adolescents.
引用
收藏
页码：347 / 354
页数：8
相关论文
共 50 条
  • [31] Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents
    Maletic, Vladimir
    Mattingly, Gregory W.
    Earnest, Jami
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2024, 24 (05) : 443 - 455
  • [32] Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, Phase III trial
    Hervas, Amaia
    Huss, Michael
    Johnson, Mats
    McNicholas, Fiona
    van Stralen, Judy
    Sreckovic, Sasha
    Lyne, Andrew
    Bloomfield, Ralph
    Sikirica, Vanja
    Robertson, Brigitte
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 (12) : 1861 - 1872
  • [33] Guanfacine Extended Release as Adjunctive Therapy to Psychostimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
    Ann C. Childress
    Advances in Therapy, 2012, 29 : 385 - 400
  • [34] Psychiatric Comorbidity in Children and Adolescents with Attention Deficit Hyperactivity Disorder
    Herguner, Sabri
    Herguner, Arzu
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2012, 49 (02): : 114 - 118
  • [35] Managing Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
    McClain, Elizabeth K.
    Burks, Erin Jewell
    PRIMARY CARE, 2015, 42 (01): : 99 - +
  • [36] Treatment of attention deficit hyperactivity disorder in children and adolescents - Safety considerations
    Wolraich, Mark L.
    McGuinn, Laura
    Doffing, Melissa
    DRUG SAFETY, 2007, 30 (01) : 17 - 26
  • [37] Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy
    Schneider, Gary
    Banaschewski, Tobias
    Feldman, Brian L.
    Gustafsson, Per A.
    Murphy, Brian
    Reynolds, Matthew
    Coghill, David R.
    Spalding, William M.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2019, 29 (04) : 285 - 304
  • [38] Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents
    Punja, Salima
    Shamseer, Larissa
    Hartling, Lisa
    Urichuk, Liana
    Vandermeer, Ben
    Nikles, Jane
    Vohra, Sunita
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (02):
  • [39] Pharmacokinetics and Pharmacodynamics of Guanfacine Extended Release in Adolescents Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder
    Martin, Patrick
    Satin, Lawrence
    Vince, Bradley D.
    Padilla, Americo F.
    White, Carla
    Corcoran, Mary
    Stevenson, Annette
    Ermer, James
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (04): : 252 - 261
  • [40] The effect of guanfacine treatment on ocular parameters in pediatric and adolescents patients with attention-deficit/hyperactivity disorder
    Torun, Isil Merve
    Pinar, Zeynep Vatansever
    Ilhan, Seyma
    BMC OPHTHALMOLOGY, 2025, 25 (01)
12345